Skip to main content

Advertisement

SpringerLink
Log in

Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Angiogenesis has always been considered as a fundamental therapeutic target for inhibiting tumor growth and metastasis. To date, anti-angiogenic treatments that have been approved are principally based on either administration of monoclonal antibodies targeting the vascular endothelial growth factor/vascular endothelial growth factor receptor axis or multikinase inhibitors. However, a growing body of evidence is pointing out the role of different classes of enzymes involved in tumor-driven angiogenesis, whose inhibition in preclinical models has already shown encouraging results. This review provides an overview on the current knowledge of potential enzymatic targets involved in tumor-driven angiogenesis and the potential clinical applications deriving from their modulation. Metalloproteinase and nitric oxide synthase inhibitors have been found to be, respectively, inefficacious or unsuitable for clinical applications. Conversely, early clinical studies evaluating the inhibition of heparanase, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, lysyl oxidase (LOX) and angiotensin-converting enzyme (ACE) have shown promising results. Therefore, preliminary evidence indicates that heparanase, NADPH oxidase, LOX and ACE might represent potential targets for anticancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.

    Article  CAS  PubMed  Google Scholar 

  2. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.

    Article  CAS  PubMed  Google Scholar 

  3. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–14.

    Article  CAS  PubMed  Google Scholar 

  4. Tewari KS, Sill M, Long HJ, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. New Eng J Med. 2014;370:734–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.

    Article  CAS  PubMed  Google Scholar 

  6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  CAS  PubMed  Google Scholar 

  7. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.

    Article  CAS  PubMed  Google Scholar 

  9. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.

    Article  CAS  PubMed  Google Scholar 

  10. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722–31.

    Article  CAS  PubMed  Google Scholar 

  11. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14:552–62.

    Article  CAS  PubMed  Google Scholar 

  12. Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14:1287–94.

    Article  CAS  PubMed  Google Scholar 

  13. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35:591–7.

    Article  PubMed  Google Scholar 

  14. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.

    Article  CAS  PubMed  Google Scholar 

  15. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143–55.

    Article  CAS  PubMed  Google Scholar 

  16. Ronca R, Benkheil M, Mitola S, Struyf S, Liekens S. Tumor angiogenesis revisited: regulators and clinical implications. Med Res Rev. 2017;37:1231–74.

  17. Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev. 2009;29:903–53.

    Article  CAS  PubMed  Google Scholar 

  18. Goffin JR, Anderson IC, Supko JG, Eder JP Jr, Shapiro GI, Lynch TJ, et al. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2005;11:3417–24.

    Article  CAS  PubMed  Google Scholar 

  19. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004;22:4683–90.

    Article  CAS  PubMed  Google Scholar 

  20. Wall L, Talbot DC, Bradbury P, Jodrell DJ. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br J Cancer. 2004;90:800–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res. 2004;10:1971–5.

    Article  CAS  PubMed  Google Scholar 

  22. Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol. 2005;23:2831–9.

    Article  CAS  PubMed  Google Scholar 

  23. Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol. 2006;102:300–8.

    Article  CAS  PubMed  Google Scholar 

  24. Macaulay VM, O’Byrne KJ, Saunders MP, Braybrooke JP, Long L, Gleeson F, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res. 1999;5:513–20.

    CAS  PubMed  Google Scholar 

  25. Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs. 1996;14:193–202.

    Article  CAS  PubMed  Google Scholar 

  26. Cheng H, Wang L, Mollica M, Re AT, Wu S, Zuo L. Nitric oxide in cancer metastasis. Cancer Lett. 2014;353:1–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Vitecek J, Lojek A, Valacchi G, Kubala L. Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges. Mediat Inflamm. 2012;2012:318087. https://doi.org/10.1155/2012/318087.

  28. Altun A, Temiz TK, Balcı E, Polat ZA, Turan M. Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination. Chin J Cancer Res. 2013;25:572–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, et al. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010;16:1834–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Mannarino E, Pirro M. Endothelial injury and repair: a novel theory for atherosclerosis. Angiology. 2008;59:69–72.

    Article  Google Scholar 

  32. Pirro M, Schillaci G, Romagno PF, Mannarino MR, Bagaglia F, Razzi R, et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. J Cardiovasc Pharmacol Ther. 2009;14:14–21.

    Article  CAS  PubMed  Google Scholar 

  33. Pirro M, Bagaglia F, Paoletti L, Razzi R, Mannarino MR. Hypercholesterolemia-associated endothelial progenitor cell dysfunction. Ther Adv Cardiovasc Dis. 2008;2:329–39.

    Article  PubMed  Google Scholar 

  34. Lin Z, Zhang Q, Luo W. Angiogenesis inhibitors as therapeutic agents in cancer: challenges and future directions. Eur J Pharmacol. 2016;793:76–81.

    Article  CAS  PubMed  Google Scholar 

  35. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013;328:18–26.

    Article  CAS  PubMed  Google Scholar 

  36. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Ucuzian AA, Gassman AA, East AT, Greisler HP. Molecular mediators of angiogenesis. J Burn Care Res. 2010;31:158–75.

    Article  PubMed  PubMed Central  Google Scholar 

  38. El-Kenawi AE, El-Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol. 2013;170:712–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res. 2011;1:482–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Coso S, Harrison I, Harrison CB, Vinh A, Sobey CG, Drummond GR, et al. NADPH oxidases as regulators of tumor angiogenesis: current and emerging concepts. Antioxid Redox Signal. 2012;16:1229–47.

    Article  CAS  PubMed  Google Scholar 

  41. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 2008;266:37–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Heo SH, Choi YJ, Ryoo HM, Cho JY. Expression profiling of ETS and MMP factors in VEGF-activated endothelial cells: role of MMP-10 in VEGF-induced angiogenesis. J Cell Physiol. 2010;224:734–42.

    Article  CAS  PubMed  Google Scholar 

  43. Rajashekhar G, Kamocka M, Marin A, Suckow MA, Wolter WR, Badve S, et al. Pro-inflammatory angiogenesis is mediated by p38 MAP kinase. J Cell Physiol. 2011;226:800–8.

    Article  CAS  PubMed  Google Scholar 

  44. Bhandarkar SS, Jaconi M, Fried LE, Bonner MY, Lefkove B, Govindarajan B, et al. Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest. 2009;119:2359–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Helfinger V, Henke N, Harenkamp S, Walter M, Epah J, Penski C, et al. The NADPH oxidase Nox4 mediates tumour angiogenesis. Acta Physiol (Oxf). 2016;216:435–46.

    Article  CAS  Google Scholar 

  46. Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci USA. 2002;99:715–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kobayashi S, Nojima Y, Shibuya M, Maru Y. Nox1 regulates apoptosis and potentially stimulates branching morphogenesis in sinusoidal endothelial cells. Exp Cell Res. 2004;300:455–62.

    Article  CAS  PubMed  Google Scholar 

  48. Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C, et al. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism. PLoS One. 2011;6:e14665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Altenhöfer S, Radermacher KA, Kleikers PW, Wingler K, Schmidt HH. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal. 2015;23:406–27.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Peterson SB, Liu J. Unraveling the specificity of heparanase utilizing synthetic substrates. J Biol Chem. 2010;285:14504–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 2010;277:3890–903.

    Article  CAS  PubMed  Google Scholar 

  52. Myler H, West JL. Heparanase and platelet factor-4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. J Biochem. 2002;131:913–22.

    Article  CAS  PubMed  Google Scholar 

  53. Meirovitz A, Goldberg R, Binder A, Rubinstein AM, Hermano E, Elkin M. Heparanase in inflammation and inflammation associated cancer. FEBS J. 2013;280:2307–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 2006;66:1455–63.

    Article  CAS  PubMed  Google Scholar 

  55. Watanabe M, Aoki Y, Kase H, Tanaka K. Heparanase expression and angiogenesis in endometrial cancer. Gynecol Obstet Invest. 2003;56:77–82.

    Article  CAS  PubMed  Google Scholar 

  56. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J. 2001;15:1661–3.

    CAS  PubMed  Google Scholar 

  57. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res. 2003;63:8749–56.

    CAS  PubMed  Google Scholar 

  58. Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J. 2017;284:42–55.

    Article  CAS  PubMed  Google Scholar 

  59. Franchini M, Mannucci PM. Low-molecular-weight heparins and cancer: focus on antitumoral effect. Ann Med. 2015;47:116–21.

    Article  CAS  PubMed  Google Scholar 

  60. Abu Arab W, Kotb R, Sirois M, Rousseau E. Concentration- and time-dependent effects of enoxaparin on human adenocarcinomic epithelial cell line A549 proliferation in vitro. Can J Physiol Pharmacol. 2011;89:705–11.

    Article  CAS  PubMed  Google Scholar 

  61. Mousa S, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. 2009;102:258–67.

    CAS  PubMed  Google Scholar 

  62. Mousa S, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost. 2004;92:627–33.

    CAS  PubMed  Google Scholar 

  63. Debergh I, Van Damme N, Pattyn P, Peeters M, Ceelen WP. The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model. Br J Cancer. 2010;102:837–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Vignoli A, Marchetti M, Russo L, Cantalino E, Diani E, Bonacina G, et al. LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells. Cancer Invest. 2011;29:153–61.

    Article  CAS  PubMed  Google Scholar 

  65. Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, Li C, et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost. 2007;33:557–68.

    Article  CAS  PubMed  Google Scholar 

  66. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999;59:3433–41.

    CAS  PubMed  Google Scholar 

  67. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene. 2005;24:4037–51.

    Article  CAS  PubMed  Google Scholar 

  68. Basche M, Gustafson DL, Holden SN, O’Bryant CL, Gore L, Witta S, et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res. 2006;12:5471–80.

    Article  CAS  PubMed  Google Scholar 

  69. Lewis K, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, et al. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs. 2008;26:89–94.

    Article  CAS  PubMed  Google Scholar 

  70. Chow L, Gustafson DL, O’Bryant CL, Gore L, Basche M, Holden SN, et al. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol. 2008;63:65–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Liu C, Chang J, Lee PH, Lin DY, Wu CC, Jeng LB, et al. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol. 2014;20:11384–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Dredge K, Hammond E, Davis K, Li CP, Liu L, Johnstone K, et al. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanse inhibitors for cancer therapy. Invest New Drugs. 2010;28:276–83.

    Article  CAS  PubMed  Google Scholar 

  73. Heyman B, Yang Y. Mechanisms of heparanase inhibitors in cancer therapy. Exp Hematol. 2016;44:1002–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Brennan TV, Lin L, Brandstadter JD, Rendell VR, Dredge K, Huang X, et al. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9 dependent NK cell activation. J Clin Invest. 2016;126:207–19.

    Article  PubMed  Google Scholar 

  75. Zhou H, Roy S, Cochran E, Zauaoui R, Chu CL, Duffner J, et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One. 2011;6:e21106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Ritchie J, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res. 2011;17:1382–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Ramani V, Zhan F, He J, Barbieri P, Noseda A, Tricot G, et al. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget. 2016;7:1598–607.

    Article  PubMed  Google Scholar 

  78. Cassinelli G, Lanzi C, Tortoreto M, Cominetti D, Petrangolini G, Favini E, et al. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol. 2013;85:1424–32.

    Article  CAS  PubMed  Google Scholar 

  79. Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid Res Mol Biol. 2001;70:1–32.

    Article  CAS  PubMed  Google Scholar 

  80. Mäki JM, Kivirikko KI. Cloning and characterization of a fourth human lysyl oxidase isoenzyme. Biochem J. 2001;355:381–7.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Perryman L, Erler JT. Lysyl oxidase in cancer research. Future Oncol. 2014;10:1709–17.

    Article  CAS  PubMed  Google Scholar 

  82. Pez F, Dayan F, Durivault J, Kaniewski B, Aimond G, Le Provost GS, et al. The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res. 2011;71:1647–57.

    Article  CAS  PubMed  Google Scholar 

  83. Baker AM, Bird D, Welti JC, Gourlaouen M, Lang G, Murray GI, et al. Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. Cancer Res. 2013;73:583–94.

    Article  CAS  PubMed  Google Scholar 

  84. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16:1009–17.

    Article  CAS  PubMed  Google Scholar 

  85. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112:67–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Feng Y, Ni L, Wan H, Fan L, Fei X, Ma Q, et al. Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncol Rep. 2011;26:1157–64.

    CAS  PubMed  Google Scholar 

  87. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 1996;98:671–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Buharalioglu CK, Song CY, Yaghini FA, Ghafoor HU, Motiwala M, Adris T, et al. Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation. Am J Physiol Heart Circ Physiol. 2011;301:1043–55.

    Article  Google Scholar 

  89. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ. 2011;183:1073–84.

    Article  Google Scholar 

  91. Song T, Choi CH, Kim MK, Kim ML, Yun BS, Seong SJ. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis. Eur J Cancer Prev. 2017;26:78–85.

    Article  CAS  PubMed  Google Scholar 

  92. Mocellin S, Bronte V, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev. 2007;27:317–52.

    Article  CAS  PubMed  Google Scholar 

  93. Quesada AR, Muñoz-Chápuli R, Medina MA. Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev. 2006;26:483–530.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University of Perugia, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Via Dottori, 1, 06156, Perugia, Italy

    Biagio Ricciuti, Jennifer Foglietta & Rita Chiari

  2. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Amirhossein Sahebkar

  3. Department of Hypertension, Medical University of Lodz, Lodz, Poland

    Maciej Banach

  4. Department of Medicine, University of Perugia, Perugia, Italy

    Vanessa Bianconi & Matteo Pirro

Authors
  1. Biagio Ricciuti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Foglietta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rita Chiari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amirhossein Sahebkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maciej Banach
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vanessa Bianconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Matteo Pirro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Biagio Ricciuti.

Ethics declarations

Conflict of interest

The authors confirm that they have no conflict of interest to disclose.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ricciuti, B., Foglietta, J., Chiari, R. et al. Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. Med Oncol 35, 4 (2018). https://doi.org/10.1007/s12032-017-1064-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-017-1064-5

Keywords

Search

Navigation